>that is great news for NFLD investors, as it would potentially slam the door shut for competitors like BPUR<
I’m not sure I would count BPUR as a competitor if you’re thinking in terms of commercial products during the next 5 years. If they are not out of business entirely, BPUR will probably still be running clinical trials well into the next decade.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.